Scholarlink

<p>Current immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children’s Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule. This comprised three vaccine doses for children &lt;9 years of age and two doses for those ≥9 years, with each dose administered at least 4 weeks apart. The additional vaccine dose was well-tolerated with no serious adverse events reported; it also resulted in improved geometric mean antibody titres for A/H1N1 (70 to 97, <i>p</i> = 0.003), A/H3N2 (76 to 104, <i>p</i> = 0.003) and B/Washington (148 to 179, <i>p</i> = 0.03) strains. In summary, a boosted influenza vaccine schedule is safe and improves humoral immune response, providing a readily implementable strategy to protect children undergoing treatment for cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Boosting the influenza vaccine schedule in children with cancer: a prospective open-label study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月26日

查看全文
  • Sung K. Chiu,
  • Eliska Furlong,
  • Elizabeth J. McKinnon,
  • Annette Fox,
  • Stephany Sánchez Ovando,
  • Louise Carolan,
  • Andrew McLean-Tooke,
  • Joyce Oommen,
  • Daniel K. Yeoh,
  • Laurence C. Cheung,
  • Nicholas G. Gottardo,
  • Rishi S. Kotecha

摘要

Current immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children’s Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule. This comprised three vaccine doses for children <9 years of age and two doses for those ≥9 years, with each dose administered at least 4 weeks apart. The additional vaccine dose was well-tolerated with no serious adverse events reported; it also resulted in improved geometric mean antibody titres for A/H1N1 (70 to 97, p = 0.003), A/H3N2 (76 to 104, p = 0.003) and B/Washington (148 to 179, p = 0.03) strains. In summary, a boosted influenza vaccine schedule is safe and improves humoral immune response, providing a readily implementable strategy to protect children undergoing treatment for cancer.